Scientists at the University of Göttingen developed new highly potent drugs (with an IC50 in the pico-molar range) as well as a selective tumor therapy through their prodrugs. Selectivity is achieved by antibody tumor targeting. The highly soluble prodrugs are activated into the cytotoxic drugs only at tumor site.
Further Information: PDF
MBM ScienceBridge GmbH
Phone: (0551) 30724-151
Contact
Dr. Jens-Peter Horst
